DNA - Ginkgo Bioworks Holdings, Inc. Stock Analysis | Stock Taper
Logo

About Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Jason Kelly

CEO

Jason Kelly

Compensation Summary
(Year 2022)

Salary $250,000
All Other Compensation $12,500
Total Compensation $262,500
Industry Biotechnology
Sector Healthcare
Went public April 19, 2021
Method of going public SPAC
Full time employees 834

Split Record

Date Type Ratio
2024-08-20 Reverse 1:40

ETFs Holding This Stock

Ratings Snapshot

Rating : C-

Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 4
Overall Score 1

Most Recent Analyst Grades

Grade Summary

Sell 1

Showing Top 1 of 1

Price Target

Target High $9
Target Low $9
Target Median $9
Target Consensus $9

Institutional Ownership

Summary

% Of Shares Owned 133.82%
Total Number Of Holders 219

Showing Top 3 of 219